Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Exclusion Criteria

• •Pregnant or breast feeding women
• •Primary or metastatic CNS (Central Nervous System) disease prior to study enrollment
• •Uncontrolled current illness including, but not limited to, ongoing or active infections requiring intravenous antimicrobials, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia and/or psychiatric illness or social situations that would limit compliance with study requirements
• •Known HIV infection
• •Active infection with Hepatitis B or C virus
• •Concomitant therapy in last 30 days of any of the following: cytotoxic chemotherapy, immunosuppressive agents, other investigational therapies or chronic use of systemic corticosteroids
• •Prior treatment with ibrutinib
• •Uncontrolled autoimmune hemolytic anemia (AIHA) or autoimmune thrombocytopenia (ITP).
• •Requires anticoagulation with warfarin or equivalent Vit K antagonist
• •Allergy to either ibrutinib or pacritinib or components within medication
• •Treatment with strong CYP3A4 inducer or inhibitor, for which no alternative is available.
• •Unwilling or unable to use a medically acceptable form of contraception.
• •Any gastrointestinal or metabolic condition that could interfere with the absorption of oral medication.